FIELD: medicine.
SUBSTANCE: invention relates to a method of therapeutic treatment and/or improvement of the condition of a patient with sepsis. A method of therapeutic treatment and/or improvement of the condition of a patient with sepsis involves administering a medicinal product containing thrombomodulin as an active ingredient, where the said medicinal product is administered to a patient whose International Normalized Ratio (INR) value is greater than 1.4 immediately prior to administration, where the term “immediately before administration” means a period of 1 hour, calculated retrospectively from the start of administration of a medicinal product containing thrombomodulin, where the medicinal product is administered to a patient whose platelet count is greater than 30,000/mm3 just before administration.
EFFECT: above invention provides a method of effective therapeutic treatment and/or improvement in sepsis accompanied by coagulopathy.
11 cl, 1 dwg, 4 tbl, 8 ex
Title |
Year |
Author |
Number |
THERAPY MONITORING IN TREATMENT WITH BINDING AGENT AGAINST ADRENOMEDULLIN (ADM) |
2018 |
- Struck, Joachim
- Bergmann, Andreas
|
RU2776811C2 |
ANTI-ORAI1 ANTIBODY |
2015 |
- Komai Tomoaki
- Kimura Takako
- Baba Daichi
- Onodera Yoshikuni
- Tanaka Kento
- Kagari Takashi
- Aki Anri
- Nagaoka Nobumi
|
RU2724742C2 |
GM-CSF-NEUTRALIZING ANTIBODIES FOR USE IN TREATING RHEUMATOID ARTHRITIS OR AS ANALGESICS |
2014 |
- Dr. Wagner Thomas
- Carlsson Malin
- Staum Kaltoft Margit
|
RU2714919C2 |
PREDICTION OF RISK OF DEVELOPMENT OF UNDESIRED REACTION RELATED TO ADMINISTRATION OF ANTIBODY TO ALK2 AND CAPABILITY OF RESPONDING TO TREATMENT WITH ANTIBODY TO ALK2 |
2019 |
- Katagiri Takenobu
- Tsukamoto Sho
- Kumagai Keigo
- Tsuji Shinnosuke
|
RU2783762C2 |
CD123-SPECIFIC CHIMERIC ANTIGENIC RECEPTORS FOR CANCER IMMUNOTHERAPY |
2015 |
|
RU2727290C2 |
MONOCLONAL ANTIBODY TO ACTIVATED PROTEIN FROM HUMAN AND PRODUCTION AND USE THEREOF |
2021 |
- Xu Jun
- Cheng Lu
- Yi Jiawei
- Xia Zhisong
- Liu Yeheng
|
RU2824515C1 |
ANTITUMOR AGENT AND A METHOD OF ITS EVALUATION |
2019 |
|
RU2803148C2 |
NEW FAB-FRAGMENT OF HUMAN NGF ANTIBODY |
2016 |
- Tanaka, Hirotsugu
- Fujita, Hirotada
- Aoki, Toshiaki
|
RU2729825C2 |
FGF21 Fc FUNCTION PROTEIN, GLP-1 Fc FUNCTION PROTEIN AND COMBINED THERAPEUTIC AGENT INCLUDING THEM AND THEIR USE |
2020 |
- Dun, Chzhao
- Chzhou, Chi
- Chzhan, Tsziyu
- Li, Yuanli
- Li, Tsyan
|
RU2804335C2 |
VERSIONS AND ISOFORMS OF ANTIBODIES WITH REDUCED BIOLOGICAL ACTIVITY |
2018 |
- Khosoguti Kensaku
- Kuvayama Maki
- Sejda Tifumi
- Vatanabe Esuke
- Tanaka Nobuyuki
- Sajto Satosi
- Fukuda Masakadzu
|
RU2813990C2 |